Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

Details for Australian Patent Application No. 2004257632 (hide)

Owner Gilead Sciences, Inc.

Inventors Montgomery, Alan Bruce; Keller, Manfred; Lintz, Frank-Chrisophe

Agent Spruson & Ferguson

Pub. Number AU-B-2004257632

PCT Pub. Number WO2005/007132

Priority 10/613,639 03.07.03 US; 10/882,985 30.06.04 US

Filing date 1 July 2004

Wipo publication date 27 January 2005

Acceptance publication date 30 July 2009

International Classifications

A61K 31/427 (2006.01) - not condensed and containing further heterocyclic rings

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 9/12 (2006.01) Medicinal preparations characterised by special physical form - Aerosols

A61K 38/00 (2006.01) Medicinal preparations containing peptides

Event Publications

19 January 2006 PCT application entered the National Phase

  PCT publication WO2005/007132 Priority application(s): WO2005/007132

13 November 2008 Assignment before Grant

  Corus Pharma, Inc. The application has been assigned to Gilead Sciences, Inc.

30 July 2009 Application Accepted

  Published as AU-B-2004257632

24 December 2009 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 30 Jun 2009. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

15 April 2010 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 30 Jun 2009

22 April 2010 Standard Patent Sealed

27 May 2010 Extension of Term of Standard Patents

  Gilead Sciences, Inc. The earliest first regulatory approval date provided by the patentee 04 Feb 2010 For the goods CAYSTON aztreonam

15 July 2010 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 23 Jun 2010. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

12 August 2010 Extension of Term of Standard Patents

  Gilead Sciences, Inc. The earliest first regulatory approval date provided by the patentee 04 Feb 2010 For the goods CAYSTON aztreonam Address for service in Australia: Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

2 December 2010 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 23 Jun 2010

23 December 2010 Extension granted

  Gilead Sciences, Inc. The earliest first regulatory approval date provided by the patentee 04 Feb 2010 For the goods CAYSTON aztreonam Extension of Term of patent pursuant to Section 77 expires on 04 Feb 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004257636-Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists

2004257630-Occluding device for occluding fluid flow through a body vessel